期刊文献+

半乳糖凝集素3与心力衰竭 被引量:11

下载PDF
导出
摘要 心力衰竭是一种复杂的临床症候群,为各种心脏疾病的严重阶段,是21世纪最严重的心血管疾病,目前正成为亟待解决的公共卫生问题[1]。心室重构是心力衰竭发展的基础,与心力衰竭的进展和不良预后相关,是心力衰竭临床结局的重要决定因素。近年来,延缓或减慢心室重构成为心力衰竭治疗的主要方向。
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2014年第8期875-877,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基金 辽宁省社会发展攻关计划(2013225089)
  • 相关文献

参考文献1

二级参考文献12

  • 1Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused up- date incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Re- port of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guide- lines Developed in Collaboration With the International Soci- ety for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
  • 2Nakahara S, Oka N, Wang Y, et al. Characterization of the nuclear import pathways of Galectin-3. Cancer Res 2006; 66: 9995-10006.
  • 3van Kimmenade RR, Januzzi JL Jr., Ellinor PT, et al. Utilityof amino-terminal pro-brain natriuretic peptide, Galectin-3, and apelin for the evaluation of patients with acute heart fail- ure. JAm Coll Cardio12006; 48: 1217-1224.
  • 4Lok D J, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin ResCardio12010; 99: 323-328.
  • 5Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58:88-111.
  • 6Ueland T, Aukmst P, Broch K, et al. Galectin-3 in heart fail- ure: high levels are associated with all cause mortality, lnt J Cardio12011; 150:361 364.
  • 7van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circ" Heart Fail 2013; 6: 219326.
  • 8Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of mycordial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27:589 596.
  • 9Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012; 58: 267-273.
  • 10de Boer RA, Verweij N, van Veldhuisen D J, et al. A ge- home-wide association study of circulating galectin-3. PLoS ONE 2012; 7: e47385.

共引文献28

同被引文献72

  • 1张曼,王文刚,曾定尹.法舒地尔对心力衰竭大鼠血流动力学和心肌细胞内钙离子浓度的影响[J].中国新药与临床杂志,2006,25(1):33-36. 被引量:17
  • 2无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3674
  • 3YANCY CW, JESSUP M, BOZKURT B, et al. 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16) : e240-e327.
  • 4MILLER WL, GRILL DE, STRUCK J, et al. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure [J]. Am J Cardiol, 2013, 111(6): 880-885.
  • 5HRYNCHYSHYN N, JOURDAIN P, DESNOS M, et al. Galectin- 3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart faillure[J]. Arch Cardiovasc Dis, 2013, 106(10) : 541-546.
  • 6STOISER B, MORTL D, HULSMANN M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure[J]. Eur J Clin Invest, 2006, 36 ( 11 ) : 771-778.
  • 7TENTZERIS I, JARAI R, FARHAN S, et al. Complementary role of copeptin and high - sensitivity tmponin in predicting outcome in patients with stable chronic heart failure[J]. Eur J Heart Fail, 2011, 13(7): 726-733.
  • 8SHAMA UC, POKHAREL S, van BRAKEL TJ, et al. Galectin- 3 marks activated macrophages in failure- prone hypertrophied hearts and contributes to cardic dysfuntion[J]. Circulation, 2004, 110(19): 3121-3128.
  • 9KAMAL FA, WATANABE K, MA ML, et O1. A novel phenylpy- ridazinone, T- 3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy[J]. Heart Vessels, 2011, 26(11): 81-90.
  • 10FRAGASSO G, ROSANO G, BAEK SH, et ol. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study[J]. In J Cardiol, 2013, 163(3) : 320-325.

引证文献11

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部